IHeart Japan

iHeartJapan.jp specializes in consulting and contract services for the regenerative medicine and biotech sectors. The company provides expertise in the development of regenerative medicinal products, including raw materials and manufacturing facilities. It offers advisory services for biotech startups, focusing on licensing, valuation, and due diligence for investors and investment banks. Corporate clients benefit from customized training and seminars on Japanese laws and regulatory frameworks related to regenerative medicine and biotech industries.

The company also offers differentiated cells such as cardiomyocytes, endothelial cells, mural cells, and mesenchymal stem cells derived from iPS or ES cells provided by clients. Additionally, iHeartJapan.jp provides contract services for building master cell banks (MCB) or working cell banks (WCB) using stem cells with self-renewal capabilities. Their drug screening services utilize iPSCs from patients for contract drug screening.

iHeartJapan.jp's cell processing facility is authorized by the Japanese Government to manufacture cell processing products, offering contract manufacturing services to medical institutions involved in regenerative medicine for daily practice or clinical studies.

The company's product line includes research tools and regenerative medicinal products, emphasizing consistent quality, rigorously selected iPS cells, and natural manufacturing processes with minimal intervention. Their primary cultured cells and cardiomyocytes 3D products set new standards for research quality.

Keywords: regenerative medicine, biotech valuation, custom cells, iPS cells, ES cells, drug screening, cell banks, contract manufacturing, Japanese regulatory, research tools.